BNP Paribas Financial Markets’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.87K | Sell |
211
-562
| -73% | -$6.58K | ﹤0.01% | 5427 |
|
|
2025
Q4 | $11.5K | Buy |
773
+561
| +265% | +$9.78K | ﹤0.01% | 5132 |
|
|
2025
Q3 | $4.08K | Sell |
212
-93
| -30% | -$1.48K | ﹤0.01% | 5112 |
|
|
2025
Q2 | $3.39K | Sell |
305
-2
| -0.7% | -$18 | ﹤0.01% | 5000 |
|
|
2025
Q1 | $4.3K | Sell |
307
-36
| -10% | -$564 | ﹤0.01% | 4879 |
|
|
2024
Q4 | $5.69K | Sell |
343
-5
| -1% | -$81 | ﹤0.01% | 4917 |
|
|
2024
Q3 | $6.59K | Sell |
348
-3,117
| -90% | -$63.2K | ﹤0.01% | 3823 |
|
|
2024
Q2 | $50.2K | Buy |
3,465
+1,138
| +49% | +$19K | ﹤0.01% | 3450 |
|
|
2024
Q1 | $36K | Sell |
2,327
-575
| -20% | -$12.4K | ﹤0.01% | 3604 |
|
|
2023
Q4 | $81.3K | Sell |
2,902
-9,523
| -77% | -$250K | ﹤0.01% | 3440 |
|
|
2023
Q3 | $591K | Buy |
12,425
+4,692
| +61% | +$358K | ﹤0.01% | 2631 |
|
|
2023
Q2 | $741K | Buy |
7,733
+2,956
| +62% | +$322K | ﹤0.01% | 2372 |
|
|
2023
Q1 | $542K | Buy |
4,777
+1,691
| +55% | +$183K | ﹤0.01% | 2685 |
|
|
2022
Q4 | $346K | Sell |
3,086
-1,457
| -32% | -$195K | ﹤0.01% | 2778 |
|
|
2022
Q3 | $583K | Buy |
4,543
+3,754
| +476% | +$384K | ﹤0.01% | 2877 |
|
|
2022
Q2 | $54.1K | Sell |
789
-1,549
| -66% | -$133K | ﹤0.01% | 3539 |
|
|
2022
Q1 | $333K | Sell |
2,338
-9,577
| -80% | -$1.47M | ﹤0.01% | 2947 |
|
|
2021
Q4 | $1.99M | Buy |
11,915
+11,289
| +1,803% | +$1.79M | ﹤0.01% | 2028 |
|
|
2021
Q3 | $87.2K | Buy |
626
+495
| +378% | +$96.9K | ﹤0.01% | 3327 |
|
|
2021
Q2 | $62.5K | Sell |
131
-210
| -62% | -$88.6K | ﹤0.01% | 3186 |
|
|
2021
Q1 | $140K | Buy |
341
+34
| +11% | +$15.7K | ﹤0.01% | 3199 |
|
|
2020
Q4 | $151K | Sell |
307
-319
| -51% | -$187K | ﹤0.01% | 3015 |
|
|
2020
Q3 | $354K | Buy |
626
+529
| +545% | +$176K | ﹤0.01% | 2420 |
|
|
2020
Q2 | $9.22K | Sell |
97
-471
| -83% | -$41.3K | ﹤0.01% | 3747 |
|
|
2020
Q1 | $40.5K | Buy |
568
+352
| +163% | +$23.6K | ﹤0.01% | 3642 |
|
|
2019
Q4 | $14.9K | Sell |
216
-48
| -18% | -$3.56K | ﹤0.01% | 4068 |
|
|
2019
Q3 | $21.2K | Buy |
264
+146
| +124% | +$9.65K | ﹤0.01% | 3927 |
|
|
2019
Q2 | $7.57K | Sell |
118
-99
| -46% | -$9.4K | ﹤0.01% | 4167 |
|
|
2019
Q1 | $29.8K | Buy |
217
+196
| +933% | +$23.9K | ﹤0.01% | 3774 |
|
|
2018
Q4 | $1.88K | Sell |
21
-15
| -42% | -$2.1K | ﹤0.01% | 3811 |
|
|
2018
Q3 | $5.5K | Sell |
36
-11
| -23% | -$1.78K | ﹤0.01% | 4010 |
|
|
2018
Q2 | $8.15K | Sell |
47
-172
| -79% | -$28.1K | ﹤0.01% | 3878 |
|
|
2018
Q1 | $32.1K | Buy |
219
+16
| +8% | +$3.07K | ﹤0.01% | 3761 |
|
|
2017
Q4 | $41.1K | Buy |
203
+95
| +88% | +$19.5K | ﹤0.01% | 3766 |
|
|
2017
Q3 | $34.7K | Sell |
108
-5
| -4% | -$1.37K | ﹤0.01% | 3332 |
|
|
2017
Q2 | $25.6K | Buy |
113
+95
| +528% | +$19.5K | ﹤0.01% | 3522 |
|
|
2017
Q1 | $4.14K | Sell |
18
-11
| -38% | -$2.23K | ﹤0.01% | 3354 |
|
|
2016
Q4 | $5.79K | Sell |
29
-51
| -64% | -$11.1K | ﹤0.01% | 3655 |
|
|
2016
Q3 | $19.6K | Buy |
80
+45
| +129% | +$15.8K | ﹤0.01% | 2905 |
|
|
2016
Q2 | $20.5K | Buy |
35
+25
| +250% | +$14.7K | ﹤0.01% | 2580 |
|
|
2016
Q1 | $5.42K | Sell |
10
-63
| -86% | -$32.9K | ﹤0.01% | 2271 |
|
|
2015
Q4 | $51.2K | Sell |
73
-7
| -9% | -$4.6K | ﹤0.01% | 2796 |
|
|
2015
Q3 | $47.2K | Buy |
+80
| New | +$65.3K | ﹤0.01% | 2907 |
|
Other funds holding MCRB
FP
VCM
VFT
BNP Paribas Financial Markets's MCRB Position: Q1 2026 in Review
BNP Paribas Financial Markets reduced its Seres Therapeutics (MCRB) stake by 73% in Q1 2026, selling an estimated $6.58K and leaving 211 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #5427.
BNP Paribas Financial Markets first reported a position in MCRB in Q3 2015 and has held it in 43 quarters since. The position peaked at $1.99M in Q4 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- BNP Paribas Financial Markets held 211 shares of Seres Therapeutics worth $1.87K as of Q1 2026.
- BNP Paribas Financial Markets sold 562 Seres Therapeutics shares in Q1 2026, an estimated $6.58K.
- Seres Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5427 holding.
- BNP Paribas Financial Markets first reported a position in Seres Therapeutics in Q3 2015 and has held it in 43 quarters since.
- BNP Paribas Financial Markets's Seres Therapeutics position peaked at $1.99M in Q4 2021.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.